| Entry |
|
|---|
| Name |
Antazoline phosphate (USP)
|
|---|
| Formula |
C17H19N3. H3PO4
|
|---|
| Exact mass |
363.1348
|
|---|
| Mol weight |
363.348
|
|---|
| Structure |
     |
|---|
| Activity |
Antihistaminic
|
|---|
| Remark |
|
|---|
| Target |
|
|---|
| Pathway |
hsa04020 Calcium signaling pathway
hsa04080 Neuroactive ligand-receptor interaction | |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
R RESPIRATORY SYSTEM
R01 NASAL PREPARATIONS
R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01AC Antiallergic agents, excl. corticosteroids
R01AC04 Antazoline
D02950 Antazoline phosphate (USP)
R06 ANTIHISTAMINES FOR SYSTEMIC USE
R06A ANTIHISTAMINES FOR SYSTEMIC USE
R06AX Other antihistamines for systemic use
R06AX05 Antazoline
D02950 Antazoline phosphate (USP)
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Histamine
H1-receptor [HSA:3269] [KO:K04149]
Antazoline [ATC:R01AC04 R06AX05]
D02950 Antazoline phosphate (USP)
 |
|---|
| Other DBs |
CAS: 154-68-7 PubChem: LigandBox: NIKKAJI: |
|---|
| KCF data |
ATOM 25
1 C8y C 16.0288 -15.6083
2 C8x C 16.0288 -17.0082
3 C8x C 17.2411 -17.7081
4 C8y C 18.4534 -17.0082
5 N1c N 18.4534 -15.6083
6 C1b C 17.2411 -14.9084
7 C8x C 19.6657 -17.7081
8 N2x N 20.8779 -17.0082
9 C2y C 20.8779 -15.6083
10 C1b C 19.6657 -14.9084
11 C8x C 14.8166 -14.9084
12 C8x C 13.6042 -15.6083
13 C8x C 13.6042 -17.0082
14 C8x C 14.8166 -17.7081
15 C8x C 17.2411 -19.1079
16 C8x C 18.4534 -19.8078
17 C8x C 19.6657 -19.1079
18 C1x C 22.2093 -17.4407
19 C1x C 23.0321 -16.3083
20 N1x N 22.2093 -15.1758
21 P1b P 27.5276 -16.7932
22 O1c O 27.5204 -15.3924
23 O1c O 28.9285 -16.7932
24 O1c O 26.1267 -16.7861
25 O1c O 27.5204 -18.1941
BOND 26
1 1 2 1
2 3 4 1
3 4 5 1
4 5 6 1
5 1 6 1
6 4 7 2
7 8 9 2
8 9 10 1
9 5 10 1
10 1 11 2
11 11 12 1
12 12 13 2
13 13 14 1
14 14 2 2
15 3 15 2
16 15 16 1
17 16 17 2
18 17 7 1
19 8 18 1
20 18 19 1
21 19 20 1
22 9 20 1
23 21 22 2
24 21 23 1
25 21 24 1
26 21 25 1
|
|---|
